Savara (SVRA) Other Accumulated Expenses (2012 - 2019)
Savara's (SVRA) quarterly Other Accumulated Expenses came in at $5000.0 in Q2 2019, down 87.8% on a QoQ basis from $41000.0 in Q1 2019.
Savara (SVRA) Other Accumulated Expenses (2012 - 2019) Analysis & Trends
Savara (SVRA) has 8 years of Other Accumulated Expenses data on file, last reported at $5000.0 in Q2 2019.
- On a quarterly basis, Other Accumulated Expenses changed N/A year-over-year to $5000.0 in Q2 2019; TTM through Jun 2019 was $5000.0, a N/A change from a year earlier, with the FY2018 full-year figure at $41000.0, up 485.71% from the prior year.
- Other Accumulated Expenses for Q2 2019 stood at $5000.0, down from $41000.0 in the prior quarter.
- Over the last five years, Other Accumulated Expenses for SVRA reached as high as $438000.0 in Q1 2016 and fell as low as $5000.0 in Q2 2019.
- Historically, Other Accumulated Expenses has averaged $204928.6 across 5 years, with a median of $253500.0 in 2015.
- Across the five-year window, Other Accumulated Expenses sank 96.74% in 2017 and jumped 485.71% in 2018, its largest moves.
- Year by year, Other Accumulated Expenses stood at $254000.0 in 2015, then slumped by 81.5% to $47000.0 in 2016, then slumped by 85.11% to $7000.0 in 2017, then soared by 485.71% to $41000.0 in 2018, then tumbled by 87.8% to $5000.0 in 2019.
- Per Business Quant data, the three most recent Other Accumulated Expenses figures were $5000.0 in Q2 2019, $41000.0 in Q1 2019, and $41000.0 in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Savara | 1.40 Bn | 1.40 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 5,000.00 |
| Mar 31, 2019 | 41,000.00 |
| Dec 31, 2018 | 41,000.00 |
| Dec 31, 2017 | 7,000.00 |
| Jun 30, 2017 | 11,000.00 |
| Mar 31, 2017 | 253,000.00 |
| Dec 31, 2016 | 47,000.00 |
| Sep 30, 2016 | 302,000.00 |
| Jun 30, 2016 | 337,000.00 |
| Mar 31, 2016 | 438,000.00 |
| Dec 31, 2015 | 254,000.00 |
| Sep 30, 2015 | 350,000.00 |
| Jun 30, 2015 | 436,000.00 |
| Mar 31, 2015 | 347,000.00 |
| Dec 31, 2014 | 242,000.00 |
| Sep 30, 2014 | 257,213.00 |
| Jun 30, 2014 | 215,582.00 |
| Mar 31, 2014 | 95,544.00 |
| Dec 31, 2013 | 221,000.00 |
| Sep 30, 2013 | 325,944.00 |